Table 3

Hip pain, ADL function, sport function and quality of life preoperative and postoperative scores

Follow-up timeStudyNumber of patientsScore 0–100
PreoperativePostoperativeDifference
DomainScoreMean±SDMean±SDMean (95% CI)
Pain<3 mosLarson et al2642VAS65±1828±2037 (29 to 45)
Larson et al2648VAS57±2024±1833 (25 to 41)
Zingg et al5023VAS34±2515±1519 (7 to 31)
3 to <6 mosDippmann et al2987VAS58±2430±2528 (21 to 35)
Larson et al2642VAS65±1812±1053 (47 to 59)
Larson et al2648VAS57±2013±944 (38 to 50)
Lerch et al3640HOOS53±1870±1917 (9 to 25)
Thomee et al49502HAGOS55±1973±2018 (15 to 21)
Zingg et al5023VAS34±2513±1820 (8 to 33)
6 mos to <1 yrDippmann et al2987VAS58±2423±2535 (28 to 43)
Larson et al2642VAS65±1812±1053 (47 to 60)
Larson et al2648VAS57±2011±1046 (39 to 52)
Stahelin et al4822VAS58±2114±1744 (33 to 55)
1 to <2 yrsDippmann et al2987VAS58±2428±2530 (23 to 37)
Larson et al2642VAS65±1812±1653 (46 to 61)
Larson et al2648VAS57±206±851 (45 to 57)
Zingg et al5023VAS34±2510±1723 (11 to 36)
2 to <3 yrsHorisberger et al2579VAS55±20*15±17*40 (34 to 46)
Larson et al2642VAS65±1821±2045 (36 to 53)
Larson et al2648VAS57±2012±1845 (37 to 53)
Larson et al35220VAS63±20*17±17*46 (43 to 49)
Polat et al4542VAS68±20*19±17*49 (41 to 57)
Redmond et al2869VAS57±2226±2531 (23 to 39)
Redmond et al2889VAS63±1928±2335 (29 to 41)
3 to <4 yrsLarson et al2642VAS65±1818±2247 (39 to 56)
Larson et al2648VAS57±206±1351 (44 to 58)
Nielsen et al39117NRS50±2737±2913 (5 to 21)
4 to <5 yrsLarson et al2642VAS65±1820±2245 (36 to 54)
Larson et al2648VAS57±208±1249 (42 to 56)
Palmer et al40173VAS68±1027±2241 (37 to 45)
ADL function3 to <6 mosLerch et al3640HOOS56±1974±2118 (9 to 27)
Thomee et al49502HAGOS58±2475±2218 (15 to 21)
6 mos to <1 yrFrank et al3128HOS65±1784±1319 (11 to 27)
Frank et al3132HOS66±1689±1023 (16 to 29)
1 to <2 yrsFabricant et al3021HOS77±19*92±8*15 (6 to 24)
Frank et al3128HOS65±1786±1021 (14 to 29)
Frank et al3132HOS66±1690±924 (18 to 30)
Nielsen et al39117HOS71±1785±1714 (9 to 18)
2 to <3 yrsFrank et al3128HOS65±1791±826 (19 to 33)
Frank et al3132HOS66±1692±826 (20 to 32)
Krych et al3418HOS68±19*91±19*23 (11 to 35)
Krych et al3418HOS60±19*81±19*21 (9 to 33)
Martinez et al3841HOS65±1598±433 (28 to 37)
Philippon et al42102HOS70±1988±1718 (13 to 23)
Redmond et al2869HOS65±2187±1722 (16 to 28)
Redmond et al2889HOS63±1986±1624 (18 to 29)
3 to <4 yrsPhilippon et al44153HOS66±1987±1921 (16 to 26)
Nielsen et al39117HOS71±1784±1712 (8 to 17)
≥5 yrsSkendzel et al27314HOS72±19*82±19*10 (7 to 12)
Sport function3 to <6 mosLerch et al3640HOOS40±2257±2717 (6 to 28)
Thomee et al49502HAGOS37±2257±2619 (16 to 22)
6 mos to <1 yrFrank et al3128HOS39±2464±3124 (10 to 39)
Frank et al3132HOS39±2478±1639 (29 to 49)
1 to <2 yrsFabricant et al3020HOS49±23*82±23*33 (19 to 47)
Frank et al3128HOS39±2473±1533 (23 to 44)
Frank et al3132HOS39±2483±1143 (34 to 53)
2 to <3 yrsFrank et al3128HOS39±2484±1044 (35 to 54)
Frank et al3132HOS39±2487±848 (39 to 57)
Krych et al3418HOS48±23*89±23*41 (26 to 56)
Krych et al3418HOS41±23*76±23*36 (21 to 51)
Martinez et al3841HOS29±1895±667 (61 to 73)
Philippon et al42102HOS43±2369±2326 (20 to 32)
Redmond et al2869HOS45±2675±2830 (21 to 39)
Redmond et al2889HOS40±2374±2534 (27 to 41)
3 to <4 yrsPhilippon et al44153HOS42±2372±2330 (24 to 36)
≥5 yrsSkendzel et al27314HOS46±23*77±23*31 (27 to 34)
Quality of life3 to <6 mosLerch et al3640HOOS26±1243±2717 (8 to 26)
Thomee et al49502HAGOS30±1849±2519 (16 to 22)
  • *SD was imputed from mean of other studies.

  • ADL, activity of daily living; mos, months; yrs, years; Group a, b, within-study results of different patient groups; VAS, visual analogue scale; NRS, numeric rating scale; HAGOS, Copenhagen Hip and Groin Outcome Score; HOOS, Hip Dysfunction and Osteoarthritis Outcome Score; HOS, Hip Outcome Score.